HLX-22
Based on 1 Customer Validation
HLX-22 is a humanized monoclonal antibody targeting HER2. HLX-22 induces apoptosis in HER2-overexpressing breast and gastric cancer cells combined with Trastuzumab (HY-P9907). HLX-22 has potent antitumor activity against advanced solid tumors.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.47%
- CAS. Nr.: 2851060-90-5
- Molecular Weight:144.18 kDa
-
Speicherung:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
HER2 |
In Vitro
Combined treatment with HLX22 and Trastuzumab (HY-P9907) inhibits growth and enhances apoptosis in HER2-overexpressing breast cancer cells and gastric cancer cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Anwendung
ELISA, FACS, Functional assay
Product Details
-
CAS. Nr. 2851060-90-5
-
Accession P04626
-
Synonyms AC101
-
Molecular Weight 144.18 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG1 kappa
-
Recommend Isotype Controls
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Reinheit
99.47%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Versand
Shipping with dry ice.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Keywords
- HLX-22
- 2851060-90-5
- AC101
- HLX22
- HLX 22
- AC 101
- AC-101
- EGFR
- Apoptosis
- Epidermal growth factor receptor
- ErbB-1
- HER1
- XELOX
- HER2-overexpressing solid tumors
- HER2
- HER2-overexpressing breast cancer cells
- trastuzumab
- HER2-positive advanced gastric/gastroesophageal junction cancer
- HLX02
- gastric cancer cells
- Inhibitor
- inhibitor
- inhibit